General


AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer (09-4-2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors (08-2-2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas... Continue Reading

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults (05-24-2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading

FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches (05-21-2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million people in the U.S. yet they are still a poorly... Continue Reading

What is a Venous Access Device and What Types are Used for Cancer Patients? (05-9-2018)

A venous access device (VAD) is a surgically implanted device that provides long-term access to a major vein. A VAD can be useful for patients undergoing systemic treatment with precision cancer medicines or chemotherapy because it allows for a single... Continue Reading

Lutathera Pepetide Receptor Radionuclide Therapy for NETs (05-3-2018)

CancerConnect News: Lutathera (lutetium Lu 177 dotatate) was recently approved for the treatment of neuroendocrine tumors (NETs) that typically occur in the pancreas and gastrointestinal tract. This is the first time a radioactive drug, or radiopharmaceutical,... Continue Reading

CancerConnect – Online Support & Networking for Cancer Patients (03-21-2018)

Social networking sites are rapidly growing, giving patients with cancer a place to connect with others. On line social groups on Facebook, discussion boards, and peer to peer networking connections have become widely available and serve some specific... Continue Reading

Managing a rare cancer (03-1-2018)

Managing a rare cancer diagnosis presents unique challenges. One survivor shares her tips for navigating the sometimes-murky waters. CancerConnect News: Happy New Year: January 7  (the day I became really special). On January 7, I became really special.... Continue Reading

FDA Approves Lutathera for Treatment for Certain Digestive Tract Cancers (02-6-2018)

CancerConnect News: The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors... Continue Reading

Cancer Patients are Relatively Unaware of the Role of Precision Cancer Medicine, Genomics and Biomarker Testing (01-8-2018)

CancerConnect News: Precision cancer medicines and the companion tests used to identify them are increasingly important in the management of cancer.  It is important to understand how aware patients are of these evolving treatment options and whether... Continue Reading

Next Page »